IMMEDIATE POSTPARTUM CESSATION OF TENOFOVIR IN HIGHLY VIREMIC PREGNANT MOTHERS WITH CHRONIC HEPATITIS B INFECTION: MATERNAL AND INFANT OUTCOMES

<div><p><strong><b>Background:</strong> </b></p>
<div><p><span lang="EN-US">Antiviral prophylaxis with tenofovir disoproxil fumarate (TDF) during pregnancy is the current standard of care to prevent mother-to-child transmission (MTCT) of chronic hepatitis B (CHB) infection in highly viremic mothers. We investigated the maternal and fetal outcomes in a large Chinese cohort of TDF-treated CHB pregnant subjects.</span></p></div>
<div><p></p></div>

SPLEEN STIFFNESS MEASUREMENT BY A DEDICATED 100Hz VIBRATION-CONTROLLED TRANSIENT ELASTOGRAPHY PROBE IMPROVES THE NON-INVASIVE DIAGNOSIS OF CLINICALLY SIGNIFICANT PORTAL HYPERTENSION IN A PROSPECTIVE MULTICENTER STUDY

<div><p><b>Background:</p> </b><p>Non-invasive diagnostic tools for clinically significant portal hypertension (CSPH) have been developed in the ANTICIPATE study/subsequent work (liver stiffness measurement (LSM) and platelet count (PLT) ± BMI) and endorsed by the Baveno VII consensus. A dedicated 100Hz probe for spleen stiffness measurement (SSM) substantially increased its clinical applicability, but limited data exists on the diagnostic performance of SSM (100Hz) for CSPH as well as its ability to improve the ANTICIPATE±NASH models.</p>

IMPACT OF BMI ON NIS2+TM AND ESTABLISHED NON-INVASIVE TESTS FOR THE EVALUATION OF NON-ALCOHOLIC LIVER DISEASE

<div><p><b>Background: </b>While obesity is a risk factor for NAFLD, patients across the BMI spectrum are affected by the disease, creating a need for reliable non-invasive tests (NITs) with performances that are not affected by BMI. While most of standard NITs are designed to detect advanced fibrosis, NIS2+™, an optimization of the blood-based NIS4® technology, is specifically designed to detect at-risk NASH (<span>NAS≥4; F≥2</span>).

ANTICANCER EFFECTS OF VITAMIN K COMBINED WITH TRANSARTERIAL CHEMOEMBOLIZATION IN HEPATOCELLULAR CARCINOMA; A PROSPECTIVE, RANDOMIZED TRIAL.

<div><p><b>Background: </b>We have previously reported that vitamin K dosing augments the anticancer effects of sorafenib by suppressing levels of des-γ-carboxy prothrombin (DCP), a known tumor growth and angiogenesis factor produced in HCC under sorafenib-induced ischemia. Herein, we aimed to establish whether vitamin K dosing could afford a similar anticancer effect when combined with transarterial chemoembolization (TACE), known to induce ischemic tumor necrosis in HCC.</p>

EXTRACELLULAR MATRIX PROTEIN 1 ATTENUATES HEPATIC FIBROSIS BY INHIBITING PROTEASE-MEDIATED LATENT TGF-β1 ACTIVATION

<div><p><b>Background: </b>ECM1 depletion results in excessive latent TGF-β1 activation and lethal liver fibrosis in mice. In patients suffering from chronic liver diseases, ECM1 expression gradually decreases with increasing severity of fibrosis. We investigated the underlying mechanisms of how ECM1 contributes to tissue homeostasis in healthy livers and what changes occur during CLD progression.</p>

LINKAGE OF LIVER STIFFNESS WITH COGNITIVE PERFORMANCE ACROSS THE SPECTRUM OF CHRONIC LIVER DISEASE AND IMPACT ON QOL: A MULTI-NATIONAL STUDY

<div><p><strong>Background</strong>: Quality of life and symptom management are important for patients with chronic liver disease (CLD), which can precede cirrhosis development. CLD patients with/without cirrhosis have mood disorders which affect cognition. Cognitive impairment is testing using simple (Animal naming, ANT) or more complicated [Stroop and Psychometric hepatic encephalopathy score (PHES)] but their impact on QOL across the spectrum of CLD is unclear.

A RHESUS MACAQUE MODEL OF HIV/HBV CO-INFECTION

<div><p><b>Background: </b>HBV and HIV are both major global health concerns as HBV infects 296 million people while HIV infects 38 million individuals worldwide.<sup> </sup>HIV/HBV co-infection is common due to similar routes of transmission, with an estimated 10% of HIV-infected individuals also infected with HBV. HIV/HBV co-infected individuals progress to chronic HBV infection more frequently and exhibit reduced HBV-specific T cell responses, with a higher probability of extensive liver fibrosis and hepatocellular carcinomas.

TRIPLE HORMONE RECEPTOR AGONIST RETATRUTIDE RESOLVES STEATOSIS IN >85 % OF SUBJECTS WITH MASLD AND OBESITY IN ASSOCIATION WITH IMPROVED METABOLIC HEALTH

<div><p><b>Background: </b>Retatrutide (RETA; LY3437943) is a novel triple agonist of the GIP, GLP-1 and glucagon receptors under investigation for obesity treatment. A 48-week phase 2 obesity study demonstrated weight loss of −22.8% and −24.2% with RETA 8 and 12 mg. We report effects of RETA on liver fat (LF) and correlations with metabolic measures in subjects with MASLD included in this trial.</p>

HEALTHCARE ACCESS THROUGH FACILITATED TELEMEDICINE FOR UNDERSERVED POPULATIONS: A STEPPED WEDGE CLUSTER RANDOMIZED CONTROLLED TRIAL OF HEPATITIS C VIRUS TREATMENT AMONG PERSONS WITH OPIOID USE DISORDER

<div><p><b>Background: </b>Telemedicine removes geographic and temporal obstacles to healthcare access. Few randomized trials have evaluated telemedicine effectiveness for underserved populations. We compared sustained virological response (SVR12) rates for hepatitis C virus (HCV) infection among persons with opioid use disorder through facilitated telemedicine (FTM) versus offsite liver specialist referral (usual care or UC).</p>

Subscribe to